Jipan Xie

3.4k total citations
133 papers, 2.4k citations indexed

About

Jipan Xie is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Jipan Xie has authored 133 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 33 papers in Pulmonary and Respiratory Medicine and 28 papers in Economics and Econometrics. Recurrent topics in Jipan Xie's work include Advanced Breast Cancer Therapies (20 papers), Health Systems, Economic Evaluations, Quality of Life (17 papers) and Attention Deficit Hyperactivity Disorder (16 papers). Jipan Xie is often cited by papers focused on Advanced Breast Cancer Therapies (20 papers), Health Systems, Economic Evaluations, Quality of Life (17 papers) and Attention Deficit Hyperactivity Disorder (16 papers). Jipan Xie collaborates with scholars based in United States, United Kingdom and China. Jipan Xie's co-authors include Eric Q. Wu, Vanja Sikirica, Mei Lü, James Signorovitch, Paul Hodgkins, M. Haim Erder, Keith A. Betts, Darwin R. Labarthe, Zhi-Jie Zheng and Andrew P. Yu and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Jipan Xie

130 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jipan Xie United States 24 485 393 370 351 304 133 2.4k
Machaon Bonafede United States 28 356 0.7× 333 0.8× 304 0.8× 188 0.5× 399 1.3× 153 2.8k
Beth Nordstrom United States 23 342 0.7× 224 0.6× 281 0.8× 167 0.5× 361 1.2× 80 2.8k
Lynda Doward United States 31 162 0.3× 326 0.8× 348 0.9× 478 1.4× 336 1.1× 89 3.0k
Eunice Chang United States 31 495 1.0× 550 1.4× 641 1.7× 173 0.5× 530 1.7× 161 4.3k
Charity Evans Canada 28 360 0.7× 249 0.6× 134 0.4× 199 0.6× 293 1.0× 91 2.7k
Anuja Roy United States 11 210 0.4× 359 0.9× 150 0.4× 344 1.0× 167 0.5× 41 2.2k
Mary A. De Vera Canada 35 384 0.8× 189 0.5× 355 1.0× 229 0.7× 423 1.4× 160 3.9k
Nigel Armstrong United Kingdom 26 404 0.8× 177 0.5× 554 1.5× 210 0.6× 298 1.0× 88 2.9k
María A. López-Olivo United States 34 974 2.0× 255 0.6× 470 1.3× 334 1.0× 444 1.5× 134 4.4k
Nicholas Latimer United Kingdom 29 510 1.1× 152 0.4× 319 0.9× 855 2.4× 298 1.0× 107 2.7k

Countries citing papers authored by Jipan Xie

Since Specialization
Citations

This map shows the geographic impact of Jipan Xie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jipan Xie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jipan Xie more than expected).

Fields of papers citing papers by Jipan Xie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jipan Xie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jipan Xie. The network helps show where Jipan Xie may publish in the future.

Co-authorship network of co-authors of Jipan Xie

This figure shows the co-authorship network connecting the top 25 collaborators of Jipan Xie. A scholar is included among the top collaborators of Jipan Xie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jipan Xie. Jipan Xie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wainberg, Zev A., Jipan Xie, Adriana Valderrama, et al.. (2023). Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting. Clinical Cancer Research. 29(7). 1360–1367. 2 indexed citations
2.
Desai, Nihar R., Jipan Xie, Jennifer Fine, et al.. (2023). Clinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United States. The American Journal of Cardiology. 192. 16–23. 5 indexed citations
3.
Zhang, Jun, et al.. (2022). Advancing the development of real-world data for healthcare research in China: challenges and opportunities. BMJ Open. 12(7). e063139–e063139. 7 indexed citations
4.
Hur, Peter, Esther Yi, Raluca Ionescu‐Ittu, et al.. (2021). Reasons for Initiating Canakinumab among Patients with Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease in the U.S. Real-World Settings. Rheumatology and Therapy. 9(1). 265–283. 3 indexed citations
5.
Jain, Sneha S., Jipan Xie, Jennifer Fine, et al.. (2021). Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States. Journal of Medical Economics. 24(1). 1115–1123. 24 indexed citations
6.
Huang, Min, Joyce O’Shaughnessy, Jing Zhao, et al.. (2020). Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. Cancer Research. 80(24). 5427–5434. 89 indexed citations
7.
8.
9.
10.
Li, Nanxin, et al.. (2017). Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2- metastatic breast cancer. Expert Opinion on Pharmacotherapy. 18(12). 1167–1178. 27 indexed citations
11.
Zhou, Zhou, Zheng‐Yi Zhou, Zheng‐Yi Zhou, et al.. (2017). Medication use in adults with attention deficit/hyperactivity disorder in a commercially-insured population in the United States. Current Medical Research and Opinion. 34(4). 585–592. 4 indexed citations
12.
Tang, Derek, et al.. (2017). First-line treatment disruption among post-menopausal women with HR+/HER2– metastatic breast cancer: a retrospective US claims study. Current Medical Research and Opinion. 33(12). 2137–2143. 2 indexed citations
13.
Joseph, Alain, Rajeev Ayyagari, Meng Xie, et al.. (2017). Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. European Child & Adolescent Psychiatry. 26(8). 875–897. 25 indexed citations
14.
Migden, Michael R., et al.. (2017). Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014. Journal of the American Academy of Dermatology. 77(1). 55–62.e3. 5 indexed citations
15.
Lin, Peggy L., Yanni Hao, Jipan Xie, et al.. (2015). Physician experiences and preferences in the treatment of HR+/HER2− metastatic breast cancer in the United States: a physician survey. Cancer Medicine. 5(2). 209–220. 11 indexed citations
16.
Betts, Keith A., Vanja Sikirica, Paul Hodgkins, et al.. (2014). Period Prevalence of Concomitant Psychotropic Medication Usage Among Children and Adolescents with Attention-Deficit/Hyperactivity Disorder During 2009. Journal of Child and Adolescent Psychopharmacology. 24(5). 260–268. 20 indexed citations
17.
Sikirica, Vanja, et al.. (2013). Immediate-Release Versus Extended-Release Guanfacine for Treatment of Attention-Deficit/Hyperactivity Disorder. The American Journal of Managed Care. 5. 6 indexed citations
18.
19.
20.
Erder, M. Haim, James Signorovitch, Juliana Setyawan, et al.. (2012). Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity. Journal of Medical Economics. 15(6). 1078–1087. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Machaon Bonafede Breakdown of academic impact, for papers by Beth Nordstrom Breakdown of academic impact, for papers by Lynda Doward Breakdown of academic impact, for papers by Eunice Chang Breakdown of academic impact, for papers by Charity Evans Breakdown of academic impact, for papers by Anuja Roy Breakdown of academic impact, for papers by Mary A. De Vera Breakdown of academic impact, for papers by Nigel Armstrong Breakdown of academic impact, for papers by María A. López-Olivo Breakdown of academic impact, for papers by Nicholas Latimer
Rankless by CCL
2026